The hemoglobin switch -- repression of ?-globin and activation of ?-globin expression during the transition from fetal to adult stages of erythropoiesis -- is a major paradigm for cell and developmental stage specific regulation. Given family and genetic studies demonstrating the beneficial effects of increased HbF (?2?2) in the ?-hemoglobin disorders -- sickle cell disease (SCD) and ?-thalassemia -- efforts have been directed towards manipulating the switch as a therapeutic approach. A major obstacle, however, has been ignorance regarding how the switch is achieved and ?-globin silencing is maintained in the adult. Work in our group over the past several years has established the repressor protein BCL11A as a central, quantitative regulator of the switch. Moreover, critical sequences in an erythroid-specific enhancer within the BCL11A gene are required for its expression, providing a target site for gene editing as an improved form of gene therapy for patients with ?-hemoglobin disorders. The remaining challenge now is development of therapeutic strategies based on modulation of BCL11A function with small molecules, as a means to bring mechanism-based therapy to wider populations. In this project we will focus on the BCL11A protein and address three aspects. First, following our identification of components of the nuclear matrix in association with BCL11A protein complexes, we will dissect the functional relationship between chromatin and the nuclear matrix in erythroid cells. Second, with the goal of reducing the level of BCL11A protein and relieving HbF repression, we will employ genetic and small molecule screens to test the possibility that inhibition of deubiquitylases might constitute a new therapeutic approach to HbF reactivation. Third, we will perform saturating CRISPR/Cas9 mutagenesis of the human A??? intergenic region to localize sequences required for full HbF repression, and correlate these with chromatin sites proposed to bind BCL11A. In this manner, we will identify critical cis-acting sequences bound by BCL11A, ascertain whether these are sites of chromatin-nuclear matrix interaction, and define additional DNA sequences for therapeutic genome editing. The goal of this project is to capitalize on our discovery of BCL11A as a major regulator of the hemoglobin switch and develop innovative, and non-traditional, therapeutic approaches to the hemoglobin disorders.

Public Health Relevance

Prior to birth, the principal hemoglobin in our red blood cells is fetal hemoglobin (HbF), whereas after birth, the major hemoglobin is an adult type, designated HbA. The genetic diseases, sickle cell disease (SCD) and ?-thalassemia (Cooley's anemia), are among the most prevalent genetic conditions and affect several million individuals worldwide. It is well established that HbF is able to replace HbA and ameliorate the severity of the hemoglobin disorders. Therefore, a major goal of our research is to develop methods to reactivate HbF in adults for therapy. This project is designed to develop new leads to achieve this challenging goal.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL032262-35A1
Application #
9276317
Study Section
Special Emphasis Panel (HLBP (JH))
Program Officer
Qasba, Pankaj
Project Start
Project End
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
35
Fiscal Year
2017
Total Cost
$426,728
Indirect Cost
$185,639
Name
Boston Children's Hospital
Department
Type
Independent Hospitals
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Huang, Jialiang; Liu, Xin; Li, Dan et al. (2016) Dynamic Control of Enhancer Repertoires Drives Lineage and Stage-Specific Transcription during Hematopoiesis. Dev Cell 36:9-23
Canver, Matthew C; Orkin, Stuart H (2016) Customizing the genome as therapy for the β-hemoglobinopathies. Blood 127:2536-45
Gao, Xiaofei; Lee, Hsiang-Ying; da Rocha, Edroaldo Lummertz et al. (2016) TGF-β inhibitors stimulate red blood cell production by enhancing self-renewal of BFU-E erythroid progenitors. Blood 128:2637-2641
Shi, Jiahai; Yuan, Bingbing; Hu, Wenqian et al. (2016) JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways. Exp Hematol 44:1044-1058.e5
Hagedorn, Elliott J; Cillis, Jennifer L; Curley, Caitlyn R et al. (2016) Generation of Parabiotic Zebrafish Embryos by Surgical Fusion of Developing Blastulae. J Vis Exp :
Yien, Yvette Y; Paw, Barry H (2016) A role for iron deficiency in dopaminergic neurodegeneration. Proc Natl Acad Sci U S A 113:3417-8
Nasrallah, Rabab; Fast, Eva M; Solaimani, Parham et al. (2016) Identification of novel regulators of developmental hematopoiesis using Endoglin regulatory elements as molecular probes. Blood 128:1928-1939
Masuda, Takeshi; Wang, Xin; Maeda, Manami et al. (2016) Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science 351:285-9
CHARGE Consortium Hematology Working Group (2016) Meta-analysis of rare and common exome chip variants identifies S1PR4 and other loci influencing blood cell traits. Nat Genet 48:867-76
Gao, Xin; Wu, Tongyu; Johnson, Kirby D et al. (2016) GATA Factor-G-Protein-Coupled Receptor Circuit Suppresses Hematopoiesis. Stem Cell Reports 6:368-82

Showing the most recent 10 out of 163 publications